Research Corporation Technologies

Pheon Therapeutics is a London-based company established in 2022, specializing in the development of Antibody-Drug Conjugates (ADCs) aimed at addressing a variety of difficult-to-treat cancers. The company focuses on creating next-generation ADCs, with its lead program targeting a novel antigen that is significantly expressed in solid tumors across multiple hard-to-treat cancer types. By enhancing the therapeutic options available to healthcare providers, Pheon Therapeutics aims to provide effective treatment alternatives for patients whose cancers do not respond to existing therapies.

S2 Genomics, Inc. is a company based in Livermore, California, that specializes in developing advanced spatial sequencing technology. Founded in 2016, the company focuses on creating integrated sample preparation systems that automate the processing of solid tissues and liquid samples into genomic samples. This technology allows researchers to isolate single cells or nuclei from raw tissues, facilitating genomics and cell biology studies. S2 Genomics aims to streamline the preparation process, ensuring reproducibility and minimal impact on cellular transcriptomes, thereby optimizing the quantity and quality of viable cells or nuclei derived from various tissue types.

iotaMotion, Inc. is a company based in Iowa City, Iowa, that specializes in the development and manufacture of cochlear ear implants aimed at treating hearing loss. Founded in 2015, the company has created a robotic-assisted surgical system designed to standardize the insertion of cochlear implant electrodes. This innovative technology enhances surgical precision by controlling the speed and acceleration of electrode insertion, which helps to reduce variability in surgical procedures. By personalizing the approach to each patient, iotaMotion enables surgeons to provide more accurate and tailored cochlear interventions, ultimately expanding access to these critical treatments for both patients and healthcare providers.

Pheon Therapeutics is a London-based company established in 2022, specializing in the development of Antibody-Drug Conjugates (ADCs) aimed at addressing a variety of difficult-to-treat cancers. The company focuses on creating next-generation ADCs, with its lead program targeting a novel antigen that is significantly expressed in solid tumors across multiple hard-to-treat cancer types. By enhancing the therapeutic options available to healthcare providers, Pheon Therapeutics aims to provide effective treatment alternatives for patients whose cancers do not respond to existing therapies.

Halo Labs is a life science instrumentation company based in Burlingame, California, specializing in the development of tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technologies. Halo Labs' offerings include assessment of biologics-developability, formulation development, late-stage formulation, small molecule solubility, and AAV analytics. Founded in 2011, the company has gained recognition for its innovative scientific platform, which provides critical insights into the particles involved in research processes, thereby enhancing the stability and quality assessment of biological drugs.

seqWell Inc. is a biotechnology company that specializes in gene sequencing and laboratory services, focusing on the development of innovative library preparation technology. Founded in 2014 and based in Beverly, Massachusetts, seqWell offers a range of products and services including paramagnetic beads for nucleic acid purification, library preparation kits, and customized bioinformatics support. Its technology platform facilitates simple and scalable multiplexing of hundreds to thousands of samples, eliminating the need for time-consuming normalization processes. The company markets its products through distributors in various countries, including the United States, Australia, South Korea, and several European nations, as well as through online channels. This approach enables seqWell to enhance the efficiency and consistency of DNA sequencing workflows for its clients.

Pheon Therapeutics is a London-based company established in 2022, specializing in the development of Antibody-Drug Conjugates (ADCs) aimed at addressing a variety of difficult-to-treat cancers. The company focuses on creating next-generation ADCs, with its lead program targeting a novel antigen that is significantly expressed in solid tumors across multiple hard-to-treat cancer types. By enhancing the therapeutic options available to healthcare providers, Pheon Therapeutics aims to provide effective treatment alternatives for patients whose cancers do not respond to existing therapies.

Q'Apel Medical, founded in 2016 and headquartered in Fremont, California, specializes in developing access device technology for neurovascular interventions. The company's medical devices are designed to assist physicians in overcoming challenges related to the delivery of neurovascular procedures, particularly in the treatment of stroke and cerebral aneurysms. By enhancing trackability in navigating complex neurovascular pathways, Q'Apel Medical aims to improve both clinical effectiveness and patient outcomes in these critical medical interventions.

Translational Drug Development, LLC is a biotechnology company specializing in preclinical services for oncology medicine development. Founded in 2003 and located in Scottsdale, Arizona, the company offers a range of services including regulatory strategic guidance, planning and document submission, as well as clinical trial design and execution tailored for oncology-focused organizations. Their platform is designed to support clinical programs that identify specific contexts of sensitivity for novel therapies, facilitating more effective patient benefits during clinical testing. This approach empowers oncology researchers to properly assess and prepare cancer drugs, ultimately advancing the field of cancer treatment.

Halo Labs is a life science instrumentation company based in Burlingame, California, specializing in the development of tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technologies. Halo Labs' offerings include assessment of biologics-developability, formulation development, late-stage formulation, small molecule solubility, and AAV analytics. Founded in 2011, the company has gained recognition for its innovative scientific platform, which provides critical insights into the particles involved in research processes, thereby enhancing the stability and quality assessment of biological drugs.

seqWell Inc. is a biotechnology company that specializes in gene sequencing and laboratory services, focusing on the development of innovative library preparation technology. Founded in 2014 and based in Beverly, Massachusetts, seqWell offers a range of products and services including paramagnetic beads for nucleic acid purification, library preparation kits, and customized bioinformatics support. Its technology platform facilitates simple and scalable multiplexing of hundreds to thousands of samples, eliminating the need for time-consuming normalization processes. The company markets its products through distributors in various countries, including the United States, Australia, South Korea, and several European nations, as well as through online channels. This approach enables seqWell to enhance the efficiency and consistency of DNA sequencing workflows for its clients.

Halo Labs is a life science instrumentation company based in Burlingame, California, specializing in the development of tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technologies. Halo Labs' offerings include assessment of biologics-developability, formulation development, late-stage formulation, small molecule solubility, and AAV analytics. Founded in 2011, the company has gained recognition for its innovative scientific platform, which provides critical insights into the particles involved in research processes, thereby enhancing the stability and quality assessment of biological drugs.

BioInformatics LLC is a market research and advisory company established in 1994, headquartered in Arlington, Virginia. It serves the life science, medical device, pharmaceutical, and diagnostic industries globally. The company specializes in assessing market size and attractiveness, optimizing product configurations and pricing strategies, validating corporate acquisitions, measuring brand loyalty, evaluating brand strength and positioning, and forecasting markets and technologies. BioInformatics offers custom research services such as product concept testing, customer satisfaction analysis, market attractiveness studies, and brand awareness assessments. Its clients include biotechnology companies, medical diagnostics firms, pharmaceutical corporations, professional services providers, publishers, and associations. The company's team comprises industry veterans, market research experts, consultants, and survey statisticians.

AustinPx operates as a contract development and manufacturing organization that specializes in analytical and formulation development services, as well as cGMP manufacturing for small molecule drugs. The company provides comprehensive preclinical services through Phase II formulation and process development, along with GMP manufacturing of oral dosage forms. This enables healthcare providers to concentrate on creating innovative therapeutics from poorly bioavailable drugs, ultimately delivering enhanced clinical benefits to patients.

OrthAlign, Inc. is a medical device company based in Aliso Viejo, California, specializing in surgical navigation products designed for orthopedic procedures, particularly in joint replacement surgeries. The company offers handheld devices such as KneeAlign for total knee arthroplasty, HipAlign for hip surgeries, and UniAlign for unicompartmental knee arthroplasty. These products utilize precise alignment technology in compact, single-use devices that are compatible with various implant systems. OrthAlign's tools provide critical data related to knee stability, angles, and cup placements, aiming to improve surgical outcomes and enhance patient recovery. The company serves orthopedic surgeons, hospitals, and patients through a global network of distributors, with a mission to establish a new standard of care in total joint replacement. Founded in 2004, OrthAlign was previously known as Vitruvian Orthopaedics, Inc. and rebranded in 2009.

Rubicon Genomics, Inc. is a biotechnology company based in Ann Arbor, Michigan, focused on developing nucleic acid library preparation and amplification technologies. Founded in 2000 by two faculty members from the University of Michigan, the company aims to translate human genetics research into practical medical applications. Rubicon offers a range of products, including the ThruPLEX and PicoPLEX series, which provide high sensitivity ligation-based and quasi-random primed amplification solutions for analyzing clinical research samples. These products are designed to improve the detection of DNA methylation patterns in cancer cells and facilitate non-invasive diagnostic tests by amplifying small amounts of abnormally methylated DNA found in bodily fluids. Rubicon sells its products through distributors and its online platforms, maintaining a commitment to supporting the Michigan economy while establishing itself as a leader in pre-analytical amplification technologies.

CyMedica Orthopedics, Inc. is a medical device company focused on developing and commercializing innovative products for joint injuries and the associated muscle atrophy. Founded in 2013 and based in Scottsdale, Arizona, CyMedica offers a range of orthopedic solutions that utilize proprietary neuromuscular electrical stimulation technology. Its flagship product, e-vive, provides individualized muscle stimulation therapy through a wireless and app-controlled system, allowing patients to engage in their rehabilitation while tracking progress and sharing data with clinicians. Additionally, the company offers a variety of products, including the Conductive garment, which ensures effective muscle activation, the ACL Brace for post-operative support, and The QB1 System, designed to empower patients in overcoming quadricep weakness. These devices aim to stabilize joints, prevent muscle weakening during recovery, and improve patient outcomes while reducing the likelihood of readmission.

AustinPx operates as a contract development and manufacturing organization that specializes in analytical and formulation development services, as well as cGMP manufacturing for small molecule drugs. The company provides comprehensive preclinical services through Phase II formulation and process development, along with GMP manufacturing of oral dosage forms. This enables healthcare providers to concentrate on creating innovative therapeutics from poorly bioavailable drugs, ultimately delivering enhanced clinical benefits to patients.

Providence Medical Technology is a medical device company dedicated to developing innovative solutions for cervical spine conditions in the United States and internationally. The company specializes in the design of surgical instrumentation and implants that address cervical degenerative disc disease through a unique approach to indirect decompression and fusion. Its primary offerings include the DTRAX Spinal System, which consists of single-use disposable instruments for accessing the spine via posterior incisions, and the DTRAX Cervical Cage, designed to treat cervical radiculopathy by facilitating indirect decompression and fusion. Additionally, the company provides the DTRAX Graft, a structural allograft for posterior fusion support, and the DTRAX Facet System, a sterile kit containing necessary tools and implants for single-level surgeries. Providence Medical Technology distributes its products through a network of distributors and sales representatives and is headquartered in Lafayette, California.

ClearFlow, Inc. is a medical device company specializing in the development and manufacturing of active blood and fluid evacuation systems to address catheter obstructions. The company's primary product, the PleuraFlow Active Clearance Technology system, is designed to clear chest tubes, preventing the retention of blood and fluids in the chest cavity, particularly for pediatric cardiothoracic surgery patients. This innovative technology allows for improved postoperative blood evacuation, enabling the use of minimally invasive drainage tubes, which can enhance patient comfort and reduce surgical complications. ClearFlow is expanding its product pipeline based on its proprietary technologies to tackle catheter clogging across various medical segments, including urinary and gastrointestinal catheters, as well as wound drainage. Founded in 2006 and based in Anaheim, California, the company also operates a service center in Maastricht, the Netherlands.

OrthAlign, Inc. is a medical device company based in Aliso Viejo, California, specializing in surgical navigation products designed for orthopedic procedures, particularly in joint replacement surgeries. The company offers handheld devices such as KneeAlign for total knee arthroplasty, HipAlign for hip surgeries, and UniAlign for unicompartmental knee arthroplasty. These products utilize precise alignment technology in compact, single-use devices that are compatible with various implant systems. OrthAlign's tools provide critical data related to knee stability, angles, and cup placements, aiming to improve surgical outcomes and enhance patient recovery. The company serves orthopedic surgeons, hospitals, and patients through a global network of distributors, with a mission to establish a new standard of care in total joint replacement. Founded in 2004, OrthAlign was previously known as Vitruvian Orthopaedics, Inc. and rebranded in 2009.

OrthAlign, Inc. is a medical device company based in Aliso Viejo, California, specializing in surgical navigation products designed for orthopedic procedures, particularly in joint replacement surgeries. The company offers handheld devices such as KneeAlign for total knee arthroplasty, HipAlign for hip surgeries, and UniAlign for unicompartmental knee arthroplasty. These products utilize precise alignment technology in compact, single-use devices that are compatible with various implant systems. OrthAlign's tools provide critical data related to knee stability, angles, and cup placements, aiming to improve surgical outcomes and enhance patient recovery. The company serves orthopedic surgeons, hospitals, and patients through a global network of distributors, with a mission to establish a new standard of care in total joint replacement. Founded in 2004, OrthAlign was previously known as Vitruvian Orthopaedics, Inc. and rebranded in 2009.

Esperance Pharmaceuticals Inc. is a biotechnology company based in Houston, Texas, focused on developing targeted anticancer drugs for women with ovarian and breast cancer. The company's key product, EP-100, is an oncolytic peptide designed to selectively bind to receptors for luteinizing hormone releasing hormone (LHRH) found on cancer cells, enabling it to destroy these cells while sparing normal tissue. This innovative approach allows the drug to effectively target both dividing and non-dividing cancer cells, including those resistant to traditional chemotherapy. Esperance has formed a strategic alliance with MD Anderson Cancer Center to expedite the clinical development of EP-100, further enhancing its commitment to advancing cancer treatment. The company was incorporated in 2005 and is dedicated to improving outcomes for patients through its novel therapeutic strategies.

Cylene Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of small molecule drugs that specifically target the nucleolus to combat cancer. The company specializes in nucleolus targeting agents, which are designed for treating carcinoid/neuroendocrine tumors and pediatric brain tumors, as well as serine/threonine protein kinase inhibitors. Cylene is committed to developing first-in-class targeted agents that activate p53 through a non-genotoxic pathway, thus enhancing treatment outcomes for various cancer types. Additionally, the company offers pre-clinical stage oral drug candidates. Founded in 1997 and based in San Diego, California, Cylene Pharmaceuticals continues to advance its innovative approaches in cancer therapy.

Esperance Pharmaceuticals Inc. is a biotechnology company based in Houston, Texas, focused on developing targeted anticancer drugs for women with ovarian and breast cancer. The company's key product, EP-100, is an oncolytic peptide designed to selectively bind to receptors for luteinizing hormone releasing hormone (LHRH) found on cancer cells, enabling it to destroy these cells while sparing normal tissue. This innovative approach allows the drug to effectively target both dividing and non-dividing cancer cells, including those resistant to traditional chemotherapy. Esperance has formed a strategic alliance with MD Anderson Cancer Center to expedite the clinical development of EP-100, further enhancing its commitment to advancing cancer treatment. The company was incorporated in 2005 and is dedicated to improving outcomes for patients through its novel therapeutic strategies.

Cantex Pharmaceuticals is a biotechnology company focused on developing innovative cancer treatments by modifying existing therapies. The company has two primary development programs that utilize known chemical entities to address significant unmet medical needs in oncology. One of its key products is ODSH, a low anticoagulant heparin derivative aimed at mitigating the adverse effects of chemotherapy on platelet counts. Additionally, Cantex offers Disulfiram-Copper Chelate, which employs multiple mechanisms to target cancer stem cells, making it a potential treatment option for metastatic breast cancer, pancreatic cancer, and glioblastoma. Established in 2002 and based in Weston, Florida, Cantex Pharmaceuticals is dedicated to creating safer and more effective therapeutic options for patients facing life-threatening disorders.

CryoFluor Therapeutics engages in the development of medical devices to treat various diseases using a liquid cryogenic technology.

Cantex Pharmaceuticals is a biotechnology company focused on developing innovative cancer treatments by modifying existing therapies. The company has two primary development programs that utilize known chemical entities to address significant unmet medical needs in oncology. One of its key products is ODSH, a low anticoagulant heparin derivative aimed at mitigating the adverse effects of chemotherapy on platelet counts. Additionally, Cantex offers Disulfiram-Copper Chelate, which employs multiple mechanisms to target cancer stem cells, making it a potential treatment option for metastatic breast cancer, pancreatic cancer, and glioblastoma. Established in 2002 and based in Weston, Florida, Cantex Pharmaceuticals is dedicated to creating safer and more effective therapeutic options for patients facing life-threatening disorders.

NP Photonics, Inc. develops and manufactures specialty fiber lasers, fiber amplifiers, and transport fibers for the near- and mid-infrared wavelength bands. The company offers a range of products, including micron fiber lasers, multi-channel fiber laser systems, and light sources, which are utilized in various applications such as acoustic sensing, LIDAR, coherent communication, and metrology. NP Photonics serves markets in sensing, defense, and research through distributors and sales representatives across multiple countries, including Australia, Germany, Japan, and the United Kingdom. Founded in 1998 and based in Tucson, Arizona, the company was formerly known as NP Photonic Technologies, LLC, before changing its name in August 2000.